Brandon W. Hanson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brandon W. Hanson has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Benson Edagwa
University of Nebraska Medical Center
2 shared publications - Brady Sillman
University of Nebraska Medical Center
2 shared publications - Chen Zhang
University of Nebraska Medical Center
2 shared publications - Howard E. Gendelman
University of Nebraska Medical Center
2 shared publications Mohammad Ullah Nayan
University of Nebraska Medical Center
2 shared publicationsNam Thai Hoang Le
University of Nebraska Medical Center
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Springer Nature in Research Square
An Ultra-Long-Acting Buprenorphine Prodrug Ion-Pair for Opioid Use Disorder
Opioid overdose is a significant global public health concern. While buprenorphine (BUP) is a safe and effective treatment for opioid use disorder (OUD), requirements for frequent dosing and patient tolerability to organic solvent based monthly injectables limit its use. These challenges were overcome by the development of a scalable ultra-long-acting (ULA) BUP (NM6BUP-Pamoate). The binding of a lipophilic BUP prodrug to a hydrophobic counterion generated an organic-solvent-free formulation. A single dose of NM6BUP-Pamoate administered to Sprague–Dawley rats at 45 mg/kg produced sustained effective plasma BUP levels for six months. Brain BUP concentrations exceeded the recorded plasma levels. Safety evaluations demonstrated the absence of off-target toxicities, with local and systemic tolerability. NM6BUP-Pamoate simplifies OUD treatment to optimize clinical outcomes.
- 1 November 2026
- Published by Springer Nature in Research Square
Open AccessAn Ultra-Long-Acting Buprenorphine Prodrug Ion-Pair for Opioid Use Disorder
Opioid overdose is a significant global public health concern. While buprenorphine (BUP) is a safe and effective treatment for opioid use disorder (OUD), requirements for frequent dosing and patient tolerability to organic solvent based monthly injectables limit its use. These challenges were overcome by the development of a scalable ultra-long-acting (ULA) BUP (NM6BUP-Pamoate). The binding of a lipophilic BUP prodrug to a hydrophobic counterion generated an organic-solvent-free formulation. A single dose of NM6BUP-Pamoate administered to Sprague–Dawley rats at 45 mg/kg produced sustained effective plasma BUP levels for six months. Brain BUP concentrations exceeded the recorded plasma levels. Safety evaluations demonstrated the absence of off-target toxicities, with local and systemic tolerability. NM6BUP-Pamoate simplifies OUD treatment to optimize clinical outcomes.
- Open Access
- 21 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail
Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral antiretroviral drug, into monomeric and homodimeric ester prodrugs. The homodimeric prodrug nanosuspension, NMXBIC, shows sustained plasma BIC levels > 16 times the protein-adjusted 95% inhibitory concentration (PA-IC95) for six months after a single injection in Sprague Dawley rats. The results paralleled a short PK tail with the potential for late dose forgiveness. The monomeric prodrug nanosuspension, NM2BIC, shows lower year-long plasma BIC concentrations above PA-IC95 after a single injection. After repeated injections, NMXBIC and NM2BIC are well tolerated in New Zealand White rabbits. NMXBIC’s physicochemical properties and high BIC loading/unit mass of the prodrug contribute to its unique ULA PK profile. These results support its development as a ULA formulation for HIV-1 treatment and prevention.
- 21 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAn ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail
Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral antiretroviral drug, into monomeric and homodimeric ester prodrugs. The homodimeric prodrug nanosuspension, NMXBIC, shows sustained plasma BIC levels > 16 times the protein-adjusted 95% inhibitory concentration (PA-IC95) for six months after a single injection in Sprague Dawley rats. The results paralleled a short PK tail with the potential for late dose forgiveness. The monomeric prodrug nanosuspension, NM2BIC, shows lower year-long plasma BIC concentrations above PA-IC95 after a single injection. After repeated injections, NMXBIC and NM2BIC are well tolerated in New Zealand White rabbits. NMXBIC’s physicochemical properties and high BIC loading/unit mass of the prodrug contribute to its unique ULA PK profile. These results support its development as a ULA formulation for HIV-1 treatment and prevention.